… Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20
insertion (… We conducted a retrospective cohort study to assess the clinical outcomes of EGFR …

Epidermal growth factor receptor (EGFR) exon 19 deletion (E19del) is the most common
activating mutation in advanced non–small cell lung cancer (NSCLC) and associates with the …

… reported these outcomes either for common versus uncommon mutations, or for exon 20 …
Clinical outcomes for individuals with mutations in exon 20 (excluding T790M) were an area …

… exon 14 alterations involving either splice acceptor or donor sites had similar clinical
outcomes… In addition, we report the first clinical evidence of a patient with lung adenocarcinoma …

… (RWE) studies reporting clinical outcomes for EGFR exon 20 insertion mutation-positive …
outcomes for the overall group of exon 20 insertions and either did not report outcomes for …

… of Exon 20ins, 2) the prognostic impact of Exon 20ins … and Exon 20ins, 3) treatment
patterns and clinical outcomes in … study in which patients received either erlotinib or gefitinib …

… patterns, and clinical outcomes were assessed for patients harboring EGFR exon 20ins, …
not appear to be an attractive option in this population either [19]. In Europe, no targeted …

… We sought to describe the clinical outcomes and response to … evaluated their clinical outcomes
compared with a historical … somatic alterations associated with either cohort that met our …

… Patients with active brain metastases (ie, either previously untreated or previously treated
with documented progression following treatment) were excluded. Patients with brain …

… growth factor receptor (EGFR) exon 20 insertion (ex20ins) … limited information on the clinical
outcome of these patients … either by polymerase chain reaction (PCR) for exon 18–21 or …